# Study of BC3402 in Combination With Azacitidine in Patients With MDS and CMML

> **NCT05970822** · PHASE1 · UNKNOWN · sponsor: **Biocity Biopharmaceutics Co., Ltd.** · enrollment: 32 (estimated)

## Conditions studied

- Myelodysplastic Syndromes
- Chronic Myelomonocytic Leukemia

## Interventions

- **DRUG:** BC3402
- **DRUG:** Azacitidine

## Key facts

- **NCT ID:** NCT05970822
- **Lead sponsor:** Biocity Biopharmaceutics Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-06-18
- **Primary completion:** 2025-03
- **Final completion:** 2025-12
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2023-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05970822

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05970822, "Study of BC3402 in Combination With Azacitidine in Patients With MDS and CMML". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05970822. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*